ANI Pharmaceuticals Inc (ANIP) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $1.11 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.34. Analysts had a consensus of $0.77. The company posted revenue of $31.30 million in the period, compared to analysts expectations of $27.63 million. The company’s revenue was up 60.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS.
Many Wall Street Analysts have commented on ANI Pharmaceuticals Inc. Raymond James Initiated ANI Pharmaceuticals Inc on Jun 23, 2016 to “Strong Buy”, Price Target of the shares are set at $68.ANI Pharmaceuticals Inc was Downgraded by Standpoint Research to ” Hold” on May 24, 2016.
ANI Pharmaceuticals Inc closed down -0.04 points or -0.07% at $61.02 with 1,86,729 shares getting traded on Tusday. Post opening the session at $61.08, the shares hit an intraday low of $59.95 and an intraday high of $62 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Dec 22, 2015, James G. Marken (Vice President, Operations) sold 3,500 shares at $43.26 per share price. According to the SEC, on Nov 12, 2015, Arthur Przybyl (CEO) purchased 2,500 shares at $40.95 per share price. On Mar 16, 2015, Tracy Marshbanks (director) sold 210,000 shares at $63.00 per share price, according to the Form-4 filing with the securities and exchange commission.
ANI Pharmaceuticals Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include narcotics oncolytics (anti-cancers) hormones and steroids and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette Minnesota that are capable of producing oral solid dose products as well as liquids and topicals narcotics and potent products. The Company’s branded products consist of Cortenema Lithobid Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone Fluvoxamine Maleate Hydrocortisone Enema Methazolamide Metoclopramide and Opium Tincture. The Company’s markets include hormone and steroidal drugs oncolytics and narcotics and complex formulations including extended release and combination products.